| INTRODUCTION
MYC is a proto-oncogene that encodes a basic helix-loop-helix leucine zipper (bHLH-LZ) transcriptional factor named c-MYC. Overexpression of c-MYC and MYC family proteins has been detected in numerous human cancers, including Burkitt's lymphoma (c-MYC), neuroblastoma (N-MYC), and small cell lung cancer (L-MYC). [1] [2] [3] MYC is an early response gene that is activated in response to mitogenic signals 4 and has a short half-life with tight transcriptional, post-transcriptional, and post-translational controls. [4] [5] [6] c-MYC dimerizes with MAX, and the c-MYC-MAX heterodimer can activate various genes by directly binding to a specific DNA sequence, termed E-box (5 0 -CACGTG-3 0 ). 7 E-boxes are found in the promoters of a large group of c-MYC-induced genes that also include protein-coding genes (eg telomerase reverse transcriptase
[TERT], cyclin D2 [CCND2], and ribosomal RNA genes). [8] [9] [10] In contrast, c-MYC can repress various genes, including cyclin-dependent kinase inhibitors such as P15 (CDKN2B) and P21 (CDKN1A), 11, 12 through its interaction with the zinc finger protein MIZ-1 at the initiator elements of their promoters. 11, 13 c-MYC-mediated transcriptional activation or repression of the target genes influences many biological processes, including the promotion of cell proliferation, immortalization, inhibition of terminal differentiation, and induction of apoptosis.
Transforming growth factor-beta 1 (TGF-b1)-stimulated clone 22
(TSC-22/TSC22D1) was first identified as a target gene of TGF-b1 in mouse osteosarcoma cells. 14 TSC-22 and TSC-22 family members (KIAA0669/TSC22D2, GILZ/TSC22D3, and THG-1/TSC22D4) have a conserved TSC-box and a leucine zipper domain. 15 These proteins form homo-or heterodimers with other family members. During mouse embryogenesis, TSC-22 is expressed at the site of epithelialmesenchymal interaction 16 and has transcriptional repressor activity when fused to a heterologous DNA-binding domain. 15 The expression of TSC-22 in cultured cells or in Xenopus embryo inhibits cellular proliferation. 17, 18 However, the mechanism of growth inhibition by TSC-22 has not been determined. During our trial to elucidate the mechanism of TSC-22, we found that TSC-22 bound to c-MYC.
In the present study, we investigated the regulation of c-MYC transcriptional activity by TSC-22 and showed the mechanism of growth inhibition by TSC-22. 
| MATERIALS AND METHODS

| Luciferase assay
We transfected the cells using FuGENE6 transfection reagent (Promega, Madison, WI, USA) according to the manufacturer's recommendations. Luciferase activity in the cell lysates was determined by a luciferase reporter assay system (Promega, Madison, WI, USA) using a luminometer (AutoLumat LB953; EG & G Berthold, Bad
Wildbad, Germany). Luciferase activities were normalized to b-galactosidase activity of cotransfected CH110 (GE Healthcare).
| Chromatin immunoprecipitation
ChIP was carried out as described previously, 24 with some modifica- . Following reverse-cross-linking at 65°C for 6 hours, DNA was treated with proteinase K and purified using a PCR purification kit (Qiagen, Hilden, Germany). DNA was eluted into 20 lL (immunoprecipitates) and 50 lL (input) of elution buffer, and 1 lL of this solution was used for PCR analysis using the PCR primers listed in Table S1 .
| Reverse transcription-PCR
Total RNA was isolated using ISOGEN II (Nippon Gene, Tokyo, Japan). RT was carried out using High Capacity RNA-to-cDNA Master Mix (Applied Biosystems, Foster City, CA, USA) and PCR was done using Ex Taq polymerase (TaKaRa Bio Inc., Shiga, Japan). PCR primers are listed in Table S2 .
| Immunofluorescence
Immunofluorescence in HaCaT cells stably expressing TSC-22 was hTERT E-box2-luc, along with various combinations of c-MYC and TSC-22 expression plasmids, and luciferase activity was measured. Mean AE SD. n = 3. E, Expression of P15, P21, and TERT mRNA in Mock-and FLAG-TSC-22-expressing HaCaT cells (clone #11 and #17). b-actin was used as a loading control was similarly maintained in Mock-, TSC-22-, and ID2-transfected cells ( Figure S1B ). As colony numbers and morphology were similar across groups, these data lead to the conclusion that TSC-22 specifically affects proliferation and not other differentiation parameters.
| Statistical analysis
| TSC-22 interacts with c-MYC
Next, we verified the interaction between transfected TSC-22 and endogenous c-MYC. Immunoprecipitation analysis clearly showed the interaction between FLAG-TSC-22 and c-MYC (Figure 2A ) and, furthermore, TSC-22, which is distributed mainly in nuclei, co-localized with c-MYC in the nucleus ( Figure 2B ).
| TSC-22 cancels c-MYC-mediated suppression
of P15 (CDKN2B) and P21 (CDKN1A) and enhances c-MYC-mediated activation of TERT c-MYC is known to stimulate cell growth through transcriptional downregulation of CDK inhibitors, including P15 and P21. 11, 12 We therefore investigated the binding of c-MYC to the P15 (CDKN2B, À101 to +44), P21 (CDKN1A, À152 to À12), and TERT (À204 to +53) promoters using chromatin immunoprecipitation. Recruitment of c-MYC was reduced on the P15 and P21 promoters but enhanced on the TERT promoter in TSC-22-transfected HaCaT cells ( Figure 3A) and, as shown in Figure 3B ,C, c-MYC suppressed the transcriptional activity of the P15 and P21 promoters (P15-luc and WWP-luc, | 399 respectively). Importantly, TSC-22 canceled c-MYC-mediated suppression of P15 and P21 in an expression level-dependent way. Furthermore, TSC-22 stimulated P15 and P21 promoter activity in the absence of c-MYC transfection, suggesting that TSC-22 inhibits endogenous c-MYC activity. Next, we investigated the effect of TSC-22 on c-MYC-mediated promoter activation by using the TERT promoter luciferase construct (pGL3-EBox2-luc), which contains two E-boxes that are activated by c-MYC. 8 As shown in Figure 3D , TSC-22 stimulated c-MYC-mediated activation of the TERT promoter but showed no activity in the absence of c-MYC coexpression. Corresponding to these reporter results, the amount of endogenous mRNA of P15, P21, and TERT was increased in HaCaT cells stably expressing TSC-22 ( Figure 3E ).
| LZ and N-terminal domains are required for c-MYC and TSC-22 interaction
The c-MYC family proteins possess the bHLH-LZ domain at their C-terminal. 28 We examined the bHLH-LZ domain of c-MYC for its role in the interaction with TSC-22. As shown in Figure 4A including resistance to therapy and cancer relapse. 34 In the mouse leukemia model described earlier, the recovery of TSC-22 expression increased the survival of mice with leukemia. 32 Furthermore, targeted disruption of Tsc22d1 in mice enhanced the proliferation and in vivo repopulation efficiency of hematopoietic precursor cells. 32 The results of the current study provide novel insights into 
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